By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC
» See Plans and Pricing
505(b)(2) Clinical Trials for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT01889173 | Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults | Completed | Tonix Pharmaceuticals, Inc. | Phase 1 | 2013-06-01 | Very low dose (VLD) cyclobenzaprine at bedtime has shown promise as a treatment for fibromyalgia, but the chemistry of cyclobenzaprine requires new formulation technology for bedtime use. The present trial is designed to assess the safety and tolerability of 3 different formulations of TNX-102 2.8 mg SL Tablets (a new formulation of cyclobenzaprine designed to result in increased dosage precision and decreased potential for morning grogginess) and to compare the bio-availability of 3 different formulations of TNX-102 2.8 mg SL Tablets (TNX-102 with potassium phosphate, TNX-102-B with sodium phosphate, and TNX-102-C with trisodium citrate) to that of cyclobenzaprine (5 mg tablets). |
| OTC | NCT03707795 | Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study | Recruiting | University of Kentucky | Early Phase 1 | 2017-08-21 | By doing this study the investigator hopes to learn more about a potential cause of amyotrophic lateral sclerosis (ALS) called "oxidative stress". Oxidative stress is essentially an imbalance between the production of certain chemicals in the body called "free radicals" and the ability of the body to counteract or detoxify their harmful effects through neutralization by antioxidants. It is thought that factors such as environmental exposure (chemicals and lead), diet, smoking,alcohol consumption, physical activity and psychological stress cause oxidative stress to occur inside the body. By doing this study, the investigator hopes to learn whether the FDA-approved steroid medication called Betamethasone will restore overall antioxidant activity fALS patients with mutations in the Fused in Sarcoma gene (FUS gene). Participants who agree to take part in this research study, agree to the following responsibilities: - Attend all scheduled visits - Notify the study doctor of any illnesses, unexpected or troublesome side effects, or any other medical problems that occur during the study - Be completely honest with their answers to all questions - Check with the study doctor before taking any new medications, whether prescribed or "over the counter," even vitamins and herbal supplements. |
| OTC | NCT03774498 | Effect of Different Over-the-counter Toothpastes on Enamel Remineralization | Not yet recruiting | Cairo University | N/A | 2019-01-01 | This study will be conducted to compare between recent over-the-counter toothpaste (Novamin & Fluoride) and regular over-the-counter toothpaste (Sodium Fluoride) in remineralization potential, so as to be able to know which of the toothpastes will have a better remineralization potential on demineralized enamel. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004767 | Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders | Completed | Johns Hopkins University | Phase 2 | 1985-01-01 | OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders. |
| NCT00004767 | Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders | Completed | National Center for Research Resources (NCRR) | Phase 2 | 1985-01-01 | OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders. |
| NCT00074165 | Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | Terminated | National Cancer Institute (NCI) | Phase 2 | 2003-01-01 | RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, etoposide phosphate, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Osmotic blood-brain barrier disruption uses certain drugs to open the blood vessels around the brain and allow anticancer substances to be delivered directly to the brain tumor. Chemoprotective drugs such as sodium thiosulfate may protect normal cells from the side effects of carboplatin-based chemotherapy. Combining rituximab with chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate in treating patients who have refractory or recurrent primary CNS lymphoma. |
| NCT00074165 | Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | Terminated | OHSU Knight Cancer Institute | Phase 2 | 2003-01-01 | RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, etoposide phosphate, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Osmotic blood-brain barrier disruption uses certain drugs to open the blood vessels around the brain and allow anticancer substances to be delivered directly to the brain tumor. Chemoprotective drugs such as sodium thiosulfate may protect normal cells from the side effects of carboplatin-based chemotherapy. Combining rituximab with chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate in treating patients who have refractory or recurrent primary CNS lymphoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
Condition Name
| Condition Name for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic | |
| Intervention | Trials |
| Colonoscopy | 10 |
| Healthy | 5 |
| Anterior Uveitis | 3 |
| Early Childhood Caries | 3 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Condition MeSH
| Condition MeSH for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic | |
| Intervention | Trials |
| Uveitis, Anterior | 5 |
| Dental Caries | 5 |
| Uveitis | 5 |
| Iridocyclitis | 5 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
Trials by Country
Clinical Trial Progress for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
Clinical Trial Phase
Clinical Trial Status
| Clinical Trial Status for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic | |
| Clinical Trial Phase | Trials |
| Completed | 58 |
| Recruiting | 31 |
| Not yet recruiting | 27 |
| [disabled in preview] | 8 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Sponsors for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic
Sponsor Name
| Sponsor Name for Amino Acids; Magnesium Chloride; Potassium Chloride; Sodium Chloride; Sodium Phosphate, Dibasic | |
| Sponsor | Trials |
| National Cancer Institute (NCI) | 6 |
| Erydel | 4 |
| OHSU Knight Cancer Institute | 4 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
